Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses-Reference-Cited by-同舟云学术

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses

Published:2016-10 Issue:4 Volume:138 Page:1051-1059
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Gauvreau Gail M.,Arm Jonathan P.,Boulet Louis-Philippe,Leigh Richard,Cockcroft Donald W.,Davis Beth E.,Mayers Irvin,FitzGerald J. Mark,Dahlen Barbro,Killian Kieran J.,Laviolette Michel,Carlsten Christopher,Lazarinis Nikolaos,Watson Richard M.,Milot Joanne,Swystun Veronica,Bowen Miranda,Hui Linda,Lantz Ann-Sofie,Meiser Karin,Maahs Suzanne,Lowe Philip J.,Skerjanec Andrej,Drollmann Anton,O'Byrne Paul M.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference35 articles.

1. Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review;D'Amato;Multidiscip Respir Med,2014

2. IgE and mast cells in allergic disease;Galli;Nat Med,2012

3. IgE in allergy and asthma today;Gould;Nat Rev Immunol,2008

4. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach;Meno-Tetang;Basic Clin Pharmacol Toxicol,2005

5. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma;Busse;J Allergy Clin Immunol,2001

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways;Immunological Reviews;2024-08-19

2. A Comparison of Natural and Therapeutic Anti-IgE Antibodies;Antibodies;2024-07-16

3. Sustained silencing peanut allergy by xanthopurpurin is associated with suppression of peripheral and bone marrow IgE-producing B cell;Frontiers in Immunology;2024-02-06

4. Genetically engineered biological drugs in therapeutic practice;Clinical Medicine and Pharmacology;2024-01-30

5. IgG in the control of FcεRI activation: a battle on multiple fronts;Frontiers in Immunology;2024-01-11